Diabetes Drug Lixisenatide May Slow Progress of Parkinson’s

The diabetes drug lixisenatide is in trials for the treatment of Parkinson’s. In France, results from a one year, phase 2 clinical trial has shown positive results suggesting that lixisenatide may slow the progression of the symptoms of Parkinson’s.

Read the Parkinson’s Europe piece, by Laura Vickers-Green, here.

There are interesting posts on Cure Parkinson’s website about the relationship between Parkinson’s and diabetes and more information about the lixisenatide trials; read here. Cure Parkinson’s co-funded the LixiPark trials in the UK, which are currently in Phase 3 trail.

Facebook
Twitter
LinkedIn